Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis.

By L. Richeldi, U. Costabel, M. Selman, D. S. Kim, D. Hansell, A. Nicholson, K. Brown, K. Flaherty, P. Noble, G. Raghu and 5 more. New England Journal of Medicine, 2011

1,047 citations recorded by the source corpus.

Subfields: Molecular Biology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/4f42053cdc06df5e42b4dd97683532288ad5533f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. T. Ramalingam
2. TA Wynn

In Pulmonary and Respiratory Medicine

1. TA Wynn
2. T. Ramalingam
3. H. Collard
4. G. Raghu

Citations in the corpus

• An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. (2015, methodology): “treatment in patients with IPF was evaluated in three RCTs published in two separate reports (29, 30).”
• Mechanisms of fibrosis: therapeutic translation for fibrotic disease (2012, positive): “Boehringer Ingelheim also has ongoing clinical studies with another investigational tyrosine kinase inhibitor, BIBF 1120, which showed promise in slowing lung-function decline in patients with IPF 170 .”